<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819195</url>
  </required_header>
  <id_info>
    <org_study_id>10-03877</org_study_id>
    <nct_id>NCT00819195</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis</brief_title>
  <official_title>Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teva Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce
      anti-inflammatory type II monocyte development during treatment of MS, and if these antigen
      presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Production of inflammatory cytokines by monocytes and naive T cells.</measure>
    <time_frame>0, 1, 2, 4, 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">17</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>RRMS</arm_group_label>
    <description>Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <description>Healthy control volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer acetate</intervention_name>
    <description>20 mg daily subcutaneous injection. Six-month duration.</description>
    <arm_group_label>RRMS</arm_group_label>
    <other_name>Copaxone</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood mononuclear cells (PBMC) Serum RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsing-remitting multiple sclerosis patients at the UCSF Multiple Sclerosis Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing-remitting (RR) MS patients (McDonald criteria)

          -  Ages 18-55

          -  Males and females

          -  EDSS score ≤5

          -  No prior treatment with Copaxone

          -  Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable,
             provided there is a washout period of at least one month

        Exclusion Criteria:

          -  Treatment with Tysabri, Novantrone or cyclophosphamide

          -  Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or
             methotrexate)

          -  Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott S. Zamvil, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Department of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Multiple Sclerosis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, Lee L, Patarroyo JC, Stüve O, Sobel RA, Steinman L, Zamvil SS. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 Aug;13(8):935-43. Epub 2007 Aug 5.</citation>
    <PMID>17676050</PMID>
  </reference>
  <reference>
    <citation>Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001 Mar 27;56(6):702-8.</citation>
    <PMID>11288751</PMID>
  </reference>
  <reference>
    <citation>Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005 Sep;4(9):567-75. Review.</citation>
    <PMID>16109363</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y, Jalili F, Bar-Or A. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004 Jun 1;172(11):7144-53.</citation>
    <PMID>15153538</PMID>
  </reference>
  <reference>
    <citation>Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004 Jun;127(Pt 6):1370-8. Epub 2004 Apr 16.</citation>
    <PMID>15090474</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing-remitting</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>Copaxone</keyword>
  <keyword>glatiramer acetate</keyword>
  <keyword>MS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

